Top

Published in:

Open Access 01-03-2018 | Original Article—Liver, Pancreas, and Biliary Tract

Basophils activated via TLR signaling may contribute to pathophysiology of type 1 autoimmune pancreatitis

Authors: Masato Yanagawa, Kazushige Uchida, Yugo Ando, Takashi Tomiyama, Takashi Yamaguchi, Tsukasa Ikeura, Toshiro Fukui, Akiyoshi Nishio, Yoshiko Uemura, Takayuki Miyara, Hiroyuki Okamoto, Souhei Satoi, Kazuichi Okazaki

Published in: Journal of Gastroenterology | Issue 3/2018

Abstract

Background

Pathophysiology of type 1 autoimmune pancreatitis (AIP) is still unclear. We previously reported that M2 macrophages might play an important role in type 1 AIP. Recently, it has been reported that basophils regulate differentiation to M2 macrophages. In this study, we investigated basophils from the pancreatic tissue and peripheral blood of individuals with type 1 AIP.

Methods

By using immunohistochemistry, we investigated basophils in pancreatic tissue from 13 patients with type 1 AIP and examined expression of toll-like receptors (TLRs) by these cells. Additionally, we obtained peripheral blood samples from 27 healthy subjects, 40 patients with type 1 AIP, 8 patients with alcoholic chronic pancreatitis, 10 patients with bronchial asthma, and 10 patients with atopic dermatitis, and analyzed activation of basophils by stimulating them with ligands of TLR1–9. We also compared TLR expression in basophils from the tissue and blood samples.

Results

Basophils were detected in pancreatic tissues from 10 of 13 patients with type 1 AIP. Flow cytometric analysis revealed that the ratios of basophils activated by TLR4 stimulation in type 1 AIP (9.875 ± 1.148%) and atopic dermatitis (11.768 ± 1.899%) were significantly higher than those in healthy subjects (5.051 ± 0.730%; P < 0.05). Levels of basophils activated by TLR2 stimulation were higher in seven type 1 AIP cases. Furthermore, stimulation of TLR2 and/or TLR4, which were expressed by basophils in pancreas, activated basophils in peripheral blood.

Conclusions

Basophils activated via TLR signaling may play an important role in the pathophysiology of type 1 AIP.

Okazaki K, Uchida K, Miyoshi H, et al. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allergy Immunol. 2011;41(2):126–38.CrossRefPubMed

Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol. 2000;95(10):2788–94.CrossRefPubMed

Uchida K, Miyoshi H, Ikeura T, et al. Clinical and pathophysiological issues associated with type 1 autoimmune pancreatitis. Clin J Gastroenterol. 2016;9(1):7–12.CrossRefPubMed

Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas—an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.CrossRefPubMed

Kawaguchi K, Koike M, Tsuruta K, et al. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22(4):387–95.CrossRefPubMed

Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–8.CrossRefPubMed

Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–8.CrossRefPubMed

Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119–27.CrossRefPubMed

Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8.CrossRefPubMed

10.

Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.CrossRefPubMed

11.

Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1–14.CrossRefPubMed

12.

Okazaki K, Kawa S, Kamisawa T, et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas. 2009;38(8):849–66.CrossRefPubMed

13.

Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol. 2003;98(12):2811–2.CrossRefPubMed

14.

Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–5.CrossRefPubMed

15.

Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007;46(2):463–71.CrossRefPubMed

16.

Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naive and CD4 + CD25 high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008;36(2):133–40.CrossRefPubMed

17.

Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthr Rheumtol. 2012;64(1):254–63.CrossRef

18.

Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator-and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis. Pancreas. 2011;40(7):1120–30.CrossRefPubMed

19.

Uchida K, Tanaka T, Gershwin ME, et al. The geoepidemiology and clinical aspects of IgG4-related disease. Semin Liver Dis. 2016;36(3):187–99.CrossRefPubMed

20.

Fukui Y, Uchida K, Sakaguchi Y, et al. Possible involvement of Toll-like receptor 7 in the development of type 1 autoimmune pancreatitis. J Gastroenterol. 2015;50(4):435–44.CrossRefPubMed

21.

Moriyama M, Tanaka A, Maehara T, et al. T helper subsets in Sjogren’s syndrome and IgG4-related dacryoadenitis and sialoadenitis: a critical review. J Autoimmun. 2014;51:81–8.CrossRefPubMed

22.

Detlefsen S, Sipos B, Zhao J, et al. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol. 2008;32(7):986–95.CrossRefPubMed

23.

Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity. 2013;38(3):570–80.CrossRefPubMed

24.

Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood. 2000;96(13):4028–38.PubMed

25.

Devouassoux G, Foster B, Scott ML, et al. Frequency and characterization of antigen-specific IL4 and IL13 producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. J Allergy Clin Immunol. 1999;104:811–9.CrossRefPubMed

26.

Schroeder JT, MacGlashan DW Jr, Lichtenstein LM. Human basophils: mediator release and cytokine production. Adv Immunol. 2001;77:93–122.CrossRefPubMed

27.

Karasuyama H, Mukai K, Tsujimura Y, et al. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol. 2009;9(1):9–13.CrossRefPubMed

28.

Obata K, Mukai K, Tsujimura Y, et al. Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood. 2007;110(3):913–20.CrossRefPubMed

29.

Ito Y, Satoh T, Takayama K, et al. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011;66(8):1107–13.CrossRefPubMed

30.

Nirula A, Glaser SM, Kalled SL, et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23(1):119–24.CrossRefPubMed

31.

Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514.CrossRefPubMedPubMedCentral

32.

Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.CrossRefPubMed

33.

Notohara K, Wani Y, Fujisawa M. Proliferation of CD163+ spindle-shaped macrophages in IGG4-related sclerosing disease: analysis of lymphoplasmacytic sclerosing pancreatitis and sclerosing sialadenitis. Mod Pathol. 2010;23:367A.CrossRef

34.

Furukawa S, Moriyama M, Tanaka A, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156(1):9–18.CrossRefPubMed

35.

Okazaki K, Uchida K, Fukui T. Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis. J Gastroenterol. 2008;43(6):409–18.CrossRefPubMed

36.

Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol. 2011;23(5):307–15.CrossRefPubMed

37.

Fukuhara S, Moriyama M, Miyake K, et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep. 2017;7:42413.CrossRef

38.

Yoshimoto T. Basophils as Th2-inducing antigen-presenting cells. Int Immunol. 2010;22(7):543–50.CrossRefPubMed

39.

Uronen-Hansson H, Allen J, Osman M, et al. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology. 2004;111(2):173–8.CrossRefPubMedPubMedCentral

40.

Rawlings DJ, Marc A, et al. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012;12:282–94.CrossRefPubMedPubMedCentral

41.

Xu D, Komai-Koma M, Liew FY. Expression and function of Toll-like receptor on T cells. Cell Immunol. 2005;233:85–9.CrossRefPubMed

42.

Watanabe T, Yamashita K, Sakurai T, et al. Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol. 2013;48(2):247–53.CrossRefPubMed

43.

Paik WH, Ryu JK, Park JM, et al. Clinical and pathological differences between serum immunoglobulin G4-positive and -negative type 1 autoimmune pancreatitis. World J Gastroenterol. 2013;19(25):4031–8.CrossRefPubMedPubMedCentral

44.

Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol. 2011;11(12):807–22.CrossRefPubMed

45.

Clarke TB, Davis KM, Lysenko ES, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010;16(2):228–31.CrossRefPubMedPubMedCentral

46.

Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279(9):7370–7.CrossRefPubMed

47.

Hoque R, Malik AF, Gorelick F, et al. Sterile inflammatory response in acute pancreatitis. Pancreas. 2012;41(3):353–7.CrossRefPubMedPubMedCentral

48.

Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115(8):2223–33.CrossRefPubMedPubMedCentral

49.

Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201(7):1135–43.CrossRefPubMedPubMedCentral

50.

Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9.CrossRefPubMed

51.

Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205(13):3007–18.CrossRefPubMedPubMedCentral

52.

Bieneman AP, Chichester KL, Chen YH, et al. Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion. J Allergy Clin Immunol. 2005;115(2):295–301.CrossRefPubMed

53.

Suurmond J, Stoop JN, Rivellese F, et al. Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells. Eur J Immunol. 2014;44(2):386–96.CrossRefPubMed

Title: Basophils activated via TLR signaling may contribute to pathophysiology of type 1 autoimmune pancreatitis
Authors: Masato Yanagawa
Kazushige Uchida
Yugo Ando
Takashi Tomiyama
Takashi Yamaguchi
Tsukasa Ikeura
Toshiro Fukui
Akiyoshi Nishio
Yoshiko Uemura
Takayuki Miyara
Hiroyuki Okamoto
Souhei Satoi
Kazuichi Okazaki
Publication date: 01-03-2018
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 3/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-017-1390-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Basophils activated via TLR signaling may contribute to pathophysiology of type 1 autoimmune pancreatitis

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Evidence-based clinical practice guidelines for inflammatory bowel disease

Comparison of propofol with midazolam in endoscopic submucosal dissection for esophageal squamous cell carcinoma: a randomized controlled trial

Novel probiotics isolated from a Japanese traditional fermented food, Funazushi, attenuates DSS-induced colitis by increasing the induction of high integrin αv/β8-expressing dendritic cells

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis

Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan

The identification of celiac disease in asymptomatic children: the Generation R Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page